A Human Antibody against Pathologic IAPP Aggregates Protects Beta Cells in Type 2 Diabetes Models

Antibody treatment in male rats and mice transgenic for human islet amyloid polypeptide (IAPP), and human islet-engrafted mouse models of type 2 diabetes triggered clearance of (IAPP) oligomers resulting in beta cell protection and improved glucose control.